CEO: Nuno Arantes-Oliveira
Alfama is a world-leader in the development of carbon monoxide-releasing molecules (CO-RMs) as pharmaceutical agents, controlling most of the relevant IP in the field. Alfama's first clinical candidate will become the standard-of-care for liver injury: in addition Alfama controls a collection of about 1,000 CO_RMs, many of which have shown efficacy in a wide range of diseases and conditions.
CEO: Laura Cerqueira
Biomode's kits detect specific micro-organisms within hours, providing an analysis regarding the organism's resistance to antibiotics. The technology prevents prolonged and erroneous treatments, false negatives and side effects detrimental to patients.
CEO: João Fonseca
Company of development and production of innovation technologies for the market of patient-based diagnostic tests (Point-of-Care). The spinit® solution is the first and only one to allow one blood drop analysis, presenting results of parameters of different diagnostic specialties (hematology, immunoassay and clinical chemistry) in less than 5 minutes using always the same equipment of reading.
CEO: Bruno Sommer Ferreira
Provides advanced services for the development, optimisation, intensification and scale-up of industrial biotechnology processes.
CEO: Rui Brito
BSIM2 develops technology for the development of medication used to fight neurodegenerative amyloid diseases.
CEO: André Faustino
Developing genomic platforms for the reserach of gene phenotypes in fruit flies for translation to human treatment. Special focus on obesity.
CEO: Teresa Alves
Providing biopharmaceutical CMO services (Contract Manufacturing Organisation).
CEO: João Guedes
Providing software solutions to support, manage and optimise the entire clinical and administrative flow involved in clinical diagnostic imaging. The SAAS, cloud-based platform offers a single solution connecting clinical reports (RIS) and image reviewing (PACS) anywhere, anytime.
CEO: Bruno Santos
Immunethep is a biotechnology company that is a Spin-off from the University of Oporto focused on drug development for Immune System related pathologies.